Bo Bio Consult ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  20.8% 20.9% 9.6% 13.3% 22.4%  
Credit score (0-100)  6 6 25 16 3  
Credit rating  B B BB BB B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6

Net sales  0 0 0 0 0  
Gross profit  262 428 539 311 59.5  
EBITDA  34.3 17.6 68.4 -36.1 21.5  
EBIT  34.3 17.6 68.4 -36.1 21.5  
Pre-tax profit (PTP)  34.0 16.7 65.8 -35.5 21.4  
Net earnings  39.2 13.5 51.6 -35.4 21.4  
Pre-tax profit without non-rec. items  34.0 16.7 65.8 -35.5 21.4  

 
See the entire income statement

Balance sheet (kDKK) 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  38.3 51.8 103 67.9 89.3  
Interest-bearing liabilities  0.0 0.2 3.7 10.0 12.7  
Balance sheet total (assets)  78.3 103 170 93.5 108  

Net Debt  -57.3 -83.5 -72.6 -17.6 -63.9  
 
See the entire balance sheet

Volume 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  262 428 539 311 59.5  
Gross profit growth  39.3% 63.6% 25.8% -42.3% -80.9%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  78 103 170 94 108  
Balance sheet change%  114.1% 31.5% 64.8% -44.9% 15.6%  
Added value  34.3 17.6 68.4 -36.1 21.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 3.0 -1.0 1.0  

Profitability 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  13.1% 4.1% 12.7% -11.6% 36.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  59.3% 19.4% 50.2% -26.5% 21.3%  
ROI %  179.1% 39.0% 86.0% -37.8% 23.9%  
ROE %  104.6% 29.9% 66.5% -41.4% 27.2%  

Solidity 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Equity ratio %  48.9% 50.3% 60.9% 72.6% 82.6%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -167.0% -473.8% -106.1% 48.7% -297.2%  
Gearing %  0.0% 0.4% 3.6% 14.7% 14.2%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 1,034.2% 136.1% 8.9% 1.3%  

Liquidity 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Quick Ratio  2.0 2.0 2.9 3.7 5.7  
Current Ratio  2.0 2.0 2.9 3.7 5.7  
Cash and cash equivalent  57.3 83.7 76.3 27.6 76.6  

Capital use efficiency 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  38.3 51.8 111.8 67.9 89.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Net sales / employee  0 0 0 0 0  
Added value / employee  34 18 68 -36 22  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  34 18 68 -36 22  
EBIT / employee  34 18 68 -36 22  
Net earnings / employee  39 13 52 -35 21